[Possibilities for using monoclonal antibodies in diagnosis and therapy of head and neck cancers. I. Introduction and current state].
Antibodies against specific antigens may be produced through the fusion of activated B cells with myeloma cells cultured in vitro. These antibodies are secreted from the fused cells (hybridomas), which are all derived from the same clone producing monoclonal antibodies. As long as monoclonal antibodies retain their genetic information they can produce the desired antibodies. Therefore a prerequisite for the use of monoclonal antibodies is the recognition of antigens of special interest, requiring an intensive search and characterization for specificity. At present monoclonal antibodies directed against squamous cell carcinoma of the head and neck are predominantly used for immunohistology to identify the epithelial origin of the malignant cells.
Wustrow
T P
TP
Klinik und Poliklinik für Hals-Nasen-Ohrenkrank, Ludwig-Maximilians-Universität München.
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000918:Antibody Specificity / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D002460:Cell Line; D006258:Head and Neck Neoplasms / Q000175:diagnosis* / Q000276:immunology / Q000628:therapy; D006801:Humans; D014407:Tumor Cells, Cultured / Q000276:immunology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm
Verwendungsmöglichkeiten von monoklonalen Antikörpern zur Diagnose und Therapie von Kopf-Halskarzinomen. I. Einführung und derzeitiger Stand.